Ensign Peak Advisors’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Ensign Peak Advisors’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,326,062	Closed	-$5.57M	–	1795
2023 Q1	$5.57M	Hold	1,326,062	–	–	0.01%	533
2022 Q4	$7.97M	Buy	1,326,062 +619,785	+88%	+$3.38M	0.02%	463
2022 Q3	$4.11M	Buy	706,277 +557,186	+374%	+$3.47M	0.01%	568
2022 Q2	$890K	Buy	+149,091	New	+$763K	﹤0.01%	1177

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Ensign Peak Advisors's CTIC Position: Q2 2023 in Review

Ensign Peak Advisors sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 1,326,062 shares — an estimated $5.57M sold.

Ensign Peak Advisors first reported a position in CTIC in Q2 2022 and held it in 4 quarters. The position peaked at $7.97M in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Ensign Peak Advisors reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Ensign Peak Advisors sold 1,326,062 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $5.57M.
Ensign Peak Advisors first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2022 and held it in 4 quarters.
Ensign Peak Advisors's CTI BioPharma Corp. (DE) Common Stock position peaked at $7.97M in Q4 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Ensign Peak Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.